What Is Accretion/Dilution Analysis?
Accretive vs. Dilutive — What It Means
| Outcome | Definition | Market Reaction |
|---|---|---|
| Accretive | Pro forma EPS > Acquirer’s standalone EPS | Generally positive — the deal adds to per-share earnings |
| Dilutive | Pro forma EPS < Acquirer's standalone EPS | Generally negative — the deal reduces per-share earnings, at least initially |
| Breakeven | Pro forma EPS = Acquirer’s standalone EPS | Neutral on EPS — deal judged on strategic merits |
How the Analysis Works
The core logic is straightforward: combine the earnings of both companies, adjust for financing costs and synergies, then divide by the new share count. If the result is higher than the acquirer’s standalone EPS, the deal is accretive.
The specific adjustments depend on how the deal is financed:
| Financing Method | EPS Impact | Adjustment |
|---|---|---|
| All Cash | No new shares issued — no share count dilution | Subtract after-tax interest expense on new debt; subtract lost interest income on cash used |
| All Stock | New shares issued to target shareholders — increases share count | Add target’s earnings to numerator; add new shares to denominator |
| Cash + Stock Mix | Partial dilution from new shares; partial financing cost from debt/cash | Blend both adjustments proportionally |
Step-by-Step Example
Suppose Company A (acquirer) wants to buy Company B (target) using all stock:
| Metric | Company A (Acquirer) | Company B (Target) |
|---|---|---|
| Net Income | $500M | $100M |
| Shares Outstanding | 200M | 50M |
| Standalone EPS | $2.50 | $2.00 |
| Stock Price | $50 | $30 |
Company A offers a 33% premium — $40 per share for Company B. The exchange ratio is $40 ÷ $50 = 0.80 shares of A per share of B. New shares issued: 50M × 0.80 = 40M shares.
| Calculation | Value |
|---|---|
| Combined Net Income | $500M + $100M = $600M |
| Pro Forma Shares | 200M + 40M = 240M |
| Pro Forma EPS | $600M ÷ 240M = $2.50 |
| Accretion/Dilution | $2.50 − $2.50 = $0.00 (breakeven before synergies) |
Before synergies, this deal is neutral. If Company A expects $30M in after-tax synergies, pro forma EPS becomes ($600M + $30M) ÷ 240M = $2.63 — making it 5.2% accretive.
Key Drivers of Accretion/Dilution
| Driver | Accretive When… | Dilutive When… |
|---|---|---|
| Relative P/E Ratio | Acquirer’s P/E is higher than the target’s (buying cheap earnings) | Acquirer’s P/E is lower than the target’s (buying expensive earnings) |
| Financing Cost | After-tax cost of debt < target's earnings yield | After-tax cost of debt > target’s earnings yield |
| Synergies | Large, credible synergies offset premium and financing costs | Synergies are small or take years to realize |
| Premium Paid | Low premium relative to synergy value | High premium that isn’t offset by earnings or synergies |
Limitations of Accretion/Dilution Analysis
While it’s a critical screening tool, accretion/dilution analysis has important limitations. It focuses narrowly on EPS — a single metric that can be manipulated through share buybacks, accounting choices, and one-time items. A deal can be accretive to EPS but still destroy shareholder value if the acquirer overpays relative to the target’s intrinsic worth. Conversely, a strategically sound deal might be dilutive in Year 1 but create enormous long-term value.
That’s why sophisticated acquirers use accretion/dilution alongside other frameworks — including DCF analysis, comparable transaction multiples, and strategic fit assessments — rather than making it the sole decision criterion.
Key Takeaways
- Accretion/dilution analysis measures whether an acquisition increases or decreases the acquirer’s EPS.
- The analysis combines both companies’ earnings, adjusts for financing costs and synergies, and divides by the new share count.
- For all-stock deals, the relative P/E ratios of acquirer and target are the primary driver.
- For cash deals, the key comparison is the after-tax financing cost vs. the target’s earnings yield.
- EPS accretion doesn’t guarantee value creation — it’s a necessary but not sufficient condition for a good deal.
Frequently Asked Questions
Is an accretive deal always a good deal?
No. A deal can be accretive to EPS but still destroy shareholder value. For example, acquiring a low-growth, low-quality business at a cheap multiple boosts short-term EPS but may weigh down the acquirer’s valuation multiple over time. Value creation depends on whether the price paid is below the target’s intrinsic value — not just whether EPS goes up.
How do you calculate accretion/dilution for a cash deal?
For an all-cash deal, no new shares are issued, so the denominator stays the same. You subtract the after-tax cost of financing (interest on new debt or lost income on cash used) from the target’s net income. If the net contribution is positive, the deal is accretive.
Why are some dilutive deals still approved by boards?
Because the deal may be strategically compelling — entering a high-growth market, acquiring critical technology, or preventing a competitor from gaining an advantage. Boards also consider whether synergies will make the deal accretive within 1–2 years. Short-term dilution is often acceptable if the long-term value creation thesis is strong.
What is a typical accretion/dilution threshold for deal approval?
There’s no universal rule, but most acquirers target deals that are accretive to EPS within the first full year (or two years at most, including synergies). Deals projected to be dilutive beyond Year 2 face heavy scrutiny from both the board and the market.